MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
1.270
-0.110
-7.97%
After Hours: 1.310 +0.04 +3.15% 17:48 05/09 EDT
OPEN
1.370
PREV CLOSE
1.380
HIGH
1.430
LOW
1.270
VOLUME
244.57K
TURNOVER
--
52 WEEK HIGH
9.69
52 WEEK LOW
1.020
MARKET CAP
71.87M
P/E (TTM)
-1.1647
1D
5D
1M
3M
1Y
5Y
1D
What Analysts Are Saying About TScan Therapeutics Stock
Benzinga · 3d ago
TScan Therapeutics Price Target Cut to $10.00/Share From $15.00 by HC Wainwright & Co.
Dow Jones · 3d ago
TScan Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $10
Benzinga · 3d ago
TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright
TipRanks · 3d ago
TSCAN THERAPEUTICS, INC. <TCRX.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $10 FROM $15
Reuters · 3d ago
Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)
TipRanks · 3d ago
TScan Therapeutics Reports Q1 2025 Financial Results
TipRanks · 3d ago
More
About TCRX
More
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Recently
Symbol
Price
%Change

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.